Background Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by
a newly emergent coronavirus, that was first recognized in Wuhan, China, in December …

This is the first edition of this document for novel coronavirus, an adaption of WHO Clinical
management of severe acute respiratory infection when MERS-CoV infection is suspected …

ABSTRACT Since December 2019, China has been experiencing an outbreak of a new
infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Methods The original version of this document was developed in consultation with the
International Forum for Acute Care Trialists (InFACT), International Severe Acute Respiratory …

The clinical spectrum of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection ranges from asymptomatic to critical illness, which may include severe sepsis and …

What started as a cluster of patients with a mysterious respiratory illness in Wuhan, China, in
December 2019, was later determined to be coronavirus disease 2019 (COVID-19). The …

Another recent publication reported success with a combination of monoclonal antibodies, 7
days of remdesivir, and 5 days of nirmatrelvir/ritonavir [2]. Influenced by the report from …

Objective We aimed to investigate the relationship between clinical characteristics,
outcomes and the severity of severe acute respiratory syndrome coronavirus 2 pneumonia …

The coronavirus disease 2019 (COVID-19) pandemic is among the most important public
health crises of our generation. Despite the promise of prevention offered by effective …

This interim guidance document aims to help clinicians with supportive management of
patients who have acute respiratory failure and septic shock as a consequence of severe …